- Home
- INBK vs PRQR Comparison
INBK vs PRQR Comparison
Compare INBK & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INBK | PRQR |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Netherlands |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 166.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | INBK | PRQR |
|---|---|---|
| Price | $23.92 | $1.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.25 | $7.25 |
| AVG Volume (30 Days) | 56.1K | ★ 655.3K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $1.33 |
| 52 Week High | $28.51 | $3.10 |
Technical Indicators
Market Signals| Indicator | INBK | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 46.33 |
| Support Level | $23.26 | $1.51 |
| Resistance Level | $24.85 | $1.58 |
| Average True Range (ATR) | 0.79 | 0.12 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 24.68 | 42.42 |
Price Performance
Historical ComparisonAbout INBK First Internet Bancorp
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.